CLINICAL_TRIALS
trial_result
· 2011-09-02
Clinical Trial Update: Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack [Phase 1, Phase 2]
Summary
This clinical trial update summarizes safety findings from Phase 1/2 studies of KAI-9803 injected during angioplasty after a myocardial infarction.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: KAI Pharmaceuticals | Conditions: Myocardial Infarction | Phase 1, Phase 2 | Status: COMPLETED